Company Description

Affinité portable device qSPR is the world's first surface plasmon resonance (SPR) biosensor that uses a disposable cartridge for sample analysis. Compared to the large and complex SPR instrument in the market today, Affinité’s unique portable SPR design not only brings simplicity and accessibility to bio-molecular testing, but the cartridge design also gives clinicians access the power of SPR in BSL labs while minimizing risks of cross contaminations and exposure. For many researchers, having Affinité’s portable SPR represents the only accessible SPR, especially during COVID-19 lockdowns, to quickly continue developing immunoassays for cancer, rapid tests for infectious diseases, as well as doing population immunity studies. One of the main values of Affinité’s portable SPR comes from its simplicity as an on-the-bench, in-process screening that can be used as a point-of-care (PoC) diagnostic tool. By transforming the traditional reliable SPR into an accessible and simple biosensing tool, Affinité is developing medical diagnostics platform to improve success outcomes and cost of therapeutic drug monitoring (TDM) and gene therapy. 

Established in 2015 by Professor Masson and Professor Pelletier from the Université de Montréal, Affinité instruments’ foundation is built on a deep knowledge accrued on over a decade of research in SPR. The commercialization of this unique SPR innovation is spearheaded by a diverse leadership experienced in business, science and engineering. Affinité Instruments has proven use of its proprietary portable SPR technology in the areas of rapid testing through recent partnership with Canadian Universities for CHIR Canadian 2019 Novel Coronavirus (COVID-19) Rapid Research, as well as collaborations with project partners in Covid-19 PoC challenge under Innovative Solutions Canada. Affinité Instruments is part of the prestigious 2021 Canadian Technology Accelerator (CTA) Boston cohort to promote SPR as a PoC platform to simplify life science testing and diagnostics.

Cross-Validation of ELISA and a Portable Surface Plasmon Resonance Instrument for IgG Antibodies Serology with SARS-CoV-2 Positive Individuals
Djaileb, A., Jodaylami, M.H., Coutu, J., Ricard, P., Lamarre, M., Cellier-Goetghebeur, S., Charron, B., Thibault, V., Stevenson, K., Forest, S. and Live, L.S.
ChemRxiv. Cambridge: Cambridge Open Engage, 2021

A Rapid and Quantitative Serum Test for SARS-CoV-2 Antibodies with Portable Surface Plasmon Resonance Sensing.
Djaileb A, Charron B, Jodaylami MH, Thibault V, Coutu J, Stevenson K, Forest S, Live LS, Boudreau D, Pelletier JN, Masson JF.
ChemRxiv. Cambridge: Cambridge Open Engage, 2020

The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding.
Mycroft-West CJ, Su D, Li Y, Guimond SE, Rudd TR, Elli S, Miller G, Nunes QM, Procter P, Bisio A, Forsyth NR.
BioRxiv, 2020

Heparin Inhibits Cellular Invasion by SARS-CoV-2: Structural Dependence of the Interaction of the Spike S1 Receptor-Binding Domain with Heparin.
Mycroft-West CJ, Su D, Pagani I, Rudd TR, Elli S, Guimond SE, Miller G, Meneghetti MC, Nader HB, Li Y, Nunes QM.
BioRxiv. 2020

Portable and field-deployed surface plasmon resonance and plasmonic sensors
Jean-Francois Masson
Analyst, 2020,145, 3776-3800

Surface plasmon resonance clinical biosensors for medical diagnostics
Jean-Francois Masson
ACS Sensor 2017, 2, 1, 16–30

Portable Instrument & Point of Care Technologies
Masson JF, Zheng Ouyang
Analytical Methods, Issue 2016, 36

Biosensors and nanobiosensors for therapeutic drug and response monitoring
McKeating KS. Aubé A, Masson JF
Analyst 2016,141, 429-449

Miniature Multi-Channel SPR Instrument for Methotrexate Monitoring in Clinical Samples
Zhao SS, Toulouse JL, Pelechacz D, Robitaille R, Pelletier JN, Masson JF
Biosensor and Bioelectronics 2015,4, 664-670